Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2024

Original Article

GLP-1 receptor agonists and liver and cardiovascular death in patients with type 2 diabetes

Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes.

BMC Medicine

Citation & Authors

BMC Med. 2024;22(1):8.

Fu-Shun Yen; Ming-Chih Hou; James Cheng-Chung Wei; Ying-Hsiu Shih; Chii-Min Hwu; Chih-Cheng Hsu

ABSTRACT · CHINESE TRANSLATION

Translated abstract

Translated from the licensed abstract via the Chinese version. This is not an official journal translation.

background

Patients with type 2 diabetes are prone to nonalcoholic fatty liver disease and have poorer outcomes. This study compared cardiovascular disease, cirrhosis, liver-related death, and cardiovascular death between GLP-1 receptor agonist users and nonusers with type 2 diabetes but without viral hepatitis.

method

Using Taiwan’s National Health Insurance Research Database, propensity score matching identified 31,183 pairs of users and nonusers between January 1, 2008, and December 31, 2018. Outcomes were compared using multivariable-adjusted Cox proportional hazards models.

result

Median follow-up (first and third quartiles) was 2.19 (1.35, 3.52) years in users and 2.14 (1.19, 3.68) years in nonusers. All-cause mortality rates were 5.67 and 13.06 per 1,000 person-years, respectively. After multivariable adjustment, GLP-1 receptor agonist use was significantly associated with lower risks of all-cause mortality (aHR 0.48; 95% CI 0.43–0.53), cardiovascular events (0.92; 0.86–0.99), cardiovascular death (0.57; 0.45–0.72), and liver-related death (0.32; 0.13–0.75). Risks of cirrhosis, hepatic failure, and hepatocellular carcinoma did not differ significantly.

Conclusion

This nationwide cohort found that GLP-1 receptor agonist use in Taiwanese patients with type 2 diabetes was significantly associated with lower risks of all-cause mortality, cardiovascular events, and cardiovascular death. Further prospective studies are needed for confirmation.

Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.

Original work license:CC BY ↗;Translations are subject to the same licensing conditions.